Mannheim, Germany

Carsten Krantz



Average Co-Inventor Count = 5.9

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Allschwil, DE (2014)
  • Allschwll, DE (2015)
  • Mannheim, DE (2019)

Company Filing History:


Years Active: 2014-2019

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Carsten Krantz in Neurology

Introduction

Carsten Krantz is a prominent inventor located in Mannheim, Germany. With a total of three patents to his name, Krantz specializes in the field of neurology, focusing on amyloid beta(1-42) oligomers and their therapeutic applications. His groundbreaking work is vital in the diagnosis and treatment of neurodegenerative diseases.

Latest Patents

Krantz's latest patents include significant inventions surrounding amyloid beta(1-42) oligomers, derivatives thereof, and antibodies. These innovations provide a method for producing neuromodulatory oligomers of the amyloid beta protein in a reproducible manner at high yield. They are designed for use as diagnostic and therapeutic agents, aiding in the generation of oligomer-specific antibodies. The patents also cover methods for discovering substances that interact with these oligomers, enhancing the understanding of their formation and implications in neurodegenerative conditions.

Career Highlights

Carsten Krantz’s career is marked by his role at AbbVie Deutschland GmbH & Co. KG, where he contributes his expertise in developing innovative solutions for neurology. His research and patent contributions have positioned him as an influential figure in the field, underscoring the importance of his work in addressing complex neurological disorders.

Collaborations

Throughout his career, Krantz has collaborated with several notable peers, including Heinz Hillen and Andreas R. Striebinger. These partnerships have allowed him to expand the reach and impact of his inventions, fostering significant advancements in the study and treatment of amyloid-related conditions.

Conclusion

Carsten Krantz exemplifies innovation in the medical field, particularly through his contributions to understanding amyloid beta oligomers. With three patents, he continues to drive research forward at AbbVie Deutschland GmbH & Co. KG, and his collaborations with other esteemed professionals further enhance the impact of his work. His inventions hold promise for developing novel diagnostic and therapeutic approaches for neurodegenerative diseases, making a significant difference in patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…